Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish Heart Failure Registry

被引：0
|
作者：
Becher, P. M. Peter Moritz [1 ]
Savarese, G. S. [2 ]
Benson, L. [2 ]
Dahlstrom, U. [3 ,4 ]
Bhatt, D. L. [5 ]
Pitt, B. [6 ]
Lund, L. H. [2 ]
机构：
[1] Univ Heart & Vasc Ctr Hamburg, Hamburg, Germany
[2] Karolinska Univ Hosp, Cardiol, Stockholm, Sweden
[3] Linkoping Univ, Dept Cardiol, Linkoping, Sweden
[4] Linkoping Univ, Dept Hlth Med & Caring Sci, Linkoping, Sweden
[5] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Boston, MA USA
[6] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2022年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：194 / 195
页数：2
相关论文
共 50 条
  • [1] Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish heart failure registry
    Becher, Peter Moritz
    Savarese, Gianluigi
    Benson, Lina
    Dahlstrom, Ulf
    Karlstrom, Patric
    Mol, Peter G. M.
    Metra, Marco
    Bhatt, Deepak L.
    Pitt, Bertram
    Lund, Lars H.
    [J]. EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2023, 9 (04) : 343 - 352
  • [2] Sotagliflozin and decompensated heart failure: results of the SOLOIST-WHF trial
    Shah, Syed Raza
    Ali, Arroj
    Ikram, Sohail
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2021, 14 (05) : 523 - 525
  • [3] Mediators of the benefit of sotagliflozin in patients with worsening heart failure in SOLOIST-WHF
    Szarek, M.
    Bhatt, D.
    Steg, P. G.
    Davies, M. J.
    Pitt, B.
    [J]. EUROPEAN HEART JOURNAL, 2023, 44
  • [4] Eligibility for vericiguat in a real-world heart failure population according to trial, guideline and label criteria: Data from the Swedish Heart Failure Registry
    Nguyen, Ngoc V.
    Lindberg, Felix
    Benson, Lina
    Ferrannini, Giulia
    Imbalzano, Egidio
    Mol, Peter G. M.
    Dahlstrom, Ulf
    Rosano, Giuseppe M. C.
    Ezekowitz, Justin
    Butler, Javed
    Lund, Lars H.
    Savarese, Gianluigi
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2023, : 1418 - 1428
  • [5] Eligibility for EMPEROR trials in a real-world heart failure population: data from the Swedish heart failure registry
    Thorvaldsen, T.
    Lund, L. H.
    Dahlstrom, U.
    Savarese, G.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 : 326 - 327
  • [6] Eligibility for omecamtiv mecarbil in a real-world heart failure population: Data from the Swedish Heart Failure Registry
    Lindberg, Felix
    Oigaard, Natanael
    Metra, Marco
    Rosano, Giuseppe M. C.
    Dahlstrom, Ulf
    Mol, Peter
    Hage, Camilla
    Lund, Lars H.
    Savarese, Gianluigi
    [J]. PLOS ONE, 2024, 19 (05):
  • [7] TIME TO CLINICAL BENEFIT OF SOTAGLIFLOZIN IN PEOPLE WITH WORSENING HEART FAILURE IN SOLOIST-WHF
    Verma, Subodh
    Bhatt, Deepak L.
    Szarek, Michael
    Steg, Philippe Gabriel
    Pitt, Bertram
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 282 - 282
  • [8] Real-world eligibility for vericiguat according to trial, guideline, and labelling eligibility criteria: data from the Swedish Heart Failure Registry
    Nguyen, V. N.
    Lindberg, F.
    Dahlstrom, U.
    Lund, L. H.
    Savarese, G.
    [J]. EUROPEAN HEART JOURNAL, 2022, 43 : 963 - 963
  • [9] Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real-world data from the Swedish Heart Failure Registry
    Savarese, G.
    Hage, C.
    Benson, L.
    Schrage, B.
    Thorvaldsen, T.
    Lundberg, A.
    Fudim, M.
    Linde, C.
    Dahlstrom, U.
    Rosano, G. M. C.
    Lund, L. H.
    [J]. JOURNAL OF INTERNAL MEDICINE, 2021, 289 (03) : 369 - 384
  • [10] "Real World" Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry
    Simpson, Joanne
    Benson, L.
    Jhund, P. S.
    Dahlstrom, U.
    McMurray, J. J. V.
    Lund, L. H.
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 2019, 33 (03) : 315 - 322
12345